Antibodies to misfolded amyloid beta
AssigneesThe University of British Columbia, ProMIS Neurosciences Inc.
InventorsNeil R. Cashman, Johanne Kaplan, Ebrima Gibbs
Life of this patent
Estimating the term…
Abstract
The disclosure pertains to antibodies that bind A-beta oligomers and methods of using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having specific CDRs identified herein, or a sequence with at least 80% sequence identity to specific VH sequences identified herein, optionally wherein the CDR H3 amino acid sequence is as set forth in any one of SEQ ID NOs: 31-36, 38-40, or 42-50. Also provided are methods and uses thereof as well as kits comprising said antibodies.
Claims43
An antibody comprising a light chain variable region and a heavy chain variable region, the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3, the CDR-H3 having a sequence selected from any one of SEQ ID NOs:
- 31-36, 38-40 or 42-50.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An affinity matured antibody that competes for binding to cyclo(CGHHQKG) (SEQ ID NO:
- 2) peptide and/or oligomeric A-beta with a reference antibody, the reference antibody comprising CDR-H1, CDR-H2, CDRH3, CDR-L1, CDR-L2 and CDR-L3 regions as set forth in SEQ ID NOs:
- 5 to 10, respectively, or comprising a light chain variable region and a heavy chain variable region as set forth in SEQ ID NOs:
- 3 and 4, respectively, preferably wherein the antibody has at least 80%, at least 90%, or at least 95% sequence identity to the reference antibody, with the proviso that the affinity matured antibody is not the reference antibody, optionally wherein the antibody has greater differential binding activity for cyclo(CGHHQKG) (SEQ ID NO:
- 2) peptide over linear(CGHHQKG) (SEQ ID NO:
- 2) peptide than the reference antibody by at least or about 3-fold, at least or about 4-fold, at least or about 5-fold, at least or about 6-fold, at least or about 7-fold, at least or about 10-fold, at least or about 15-fold, at least or about 20-fold or at least or about 25-fold.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.